FOR us HEALTHCARE professionals only



Dolphin image for AKYNZEO

Safety profile in CINV patients

SEE THE DATA

NCCN Clinical Practice Guidelines

REVIEW NOW

AKYNZEO® demonstrated safety and efficacy over multiple cycles of chemotherapy

Study designed with patients undergoing initial and repeat cycles of chemotherapy who received AKYNZEO1

  • Multinational, multicenter, randomized, double-blind, double-dummy, parallel-group study1
  • The primary assessment of this multi-cycle study was safety, measured primarily by treatment-emergent adverse events; efficacy over multiple cycles was also evaluated1
  • Patients were randomized (3:1 for AKYNZEO) on Day 1 (AKYNZEO, n=309; aprepitant/palonosetron, n=104) of their first chemotherapy cycle before administration of1:
Highly emetogenic chemotherapy regimens (HEC)
  • Cisplatin*
  • Mechlorethamine
  • Streptozocin
  • Cyclophosphamide
    (≥1500 mg/m2)
  • Carmustine*
  • Dacarbazine*
Moderately emetogenic chemotherapy regimens (MEC)
  • Oxaliplatin*
  • Carboplatin*
  • Epirubicin*
  • Idarubicin
  • Ifosfamide
  • Irinotecan*
  • Daunorubicin*
  • Doxorubicin*
  • Cyclophosphamide*
    (<1500 mg/m2)
  • Cytarabine (>1 g/m2)
  • Azacitidine
  • Alemtuzumab
  • Bendamustine
  • Clofarabine

AKYNZEO safety and efficacy results in multi-cycle chemotherapy1

  • Treatment-emergent adverse events of AKYNZEO were comparable to aprepitant and palonosetron
  • Efficacy in the AKYNZEO arm was maintained throughout all cycles

Safety profile in CINV patients

SEE THE DATA

NCCN Clinical Practice Guidelines

REVIEW NOW
Reference: 1. Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25(7):1333-1339.